Infliximab in the treatment of plaque type psoriasis

References

• GriffthsCEMBarkerJNPathogenesis and clinical features of psoriasisLancet200737026327117658397
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLFleischerABJrReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol19994140140710459113
   PubMed Web of Science ®Google Scholar
• LebwohlMPsoriasisLancet20033611197120412686053
   PubMed Web of Science ®Google Scholar
• GreenLMeyersOLGordonWBriggsBArthritis in psoriasisAnn Rheum Dis19814043663697259328
   PubMed Web of Science ®Google Scholar
• EllisCNFradinMSMessanaJMCyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trialN Engl J Med19913242772841986287
   PubMed Web of Science ®Google Scholar
• KuijpersALvan de KerkhofPCRisk-benefit assessment of methotrexate in the treatment of severe psoriasisAm J Clin Dermatol200011273911702302
   PubMedGoogle Scholar
• GasparroFPThe role of PUVA in the treatment of psoriasis. Photobiology issues related to skin cancer incidenceAm J Clin Dermatol20001633734811702610
   PubMedGoogle Scholar
• GhoreschiKWeigertCRöckenMImmunopathogenesis and role of T cells in psoriasisClin Dermatol200725657458018021895
   PubMed Web of Science ®Google Scholar
• Santamaria BabiLFPickerLJPerez SolerMTCirculating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigenJ Exp Med19951815193519407722470
   PubMed Web of Science ®Google Scholar
• LowesMAKikuchiTFuentes-DuculanJPsoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cellsJ Invest Dermatol200812851207121118200064
   PubMed Web of Science ®Google Scholar
• NickoloffBJXinHNestleFOQinJZThe cytokine and chemokine network in psoriasisClin Dermatol200725656857318021894
   PubMed Web of Science ®Google Scholar
• BarnesPJKarinMNuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseaseN Engl J Med1997336106610729091804
   PubMed Web of Science ®Google Scholar
• SumaginRSareliusIHTNF-alpha activation of arterioles and venules alters distribution and levels of ICAM-1 and affects leukocyte-endothelial cell interactionsAm J Physiol Heart Circ Physiol20062915H2116H212516766643
   PubMed Web of Science ®Google Scholar
• KimberICumberbatchMDearmanRJBhushanMGriffithsCEMCytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilizationBr J Dermatol200014240141210735943
   PubMed Web of Science ®Google Scholar
• ZabaLCCardinaleIGilleaudeauPAmelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJ Exp Med2007204133183319418039949
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrinhHKnightDMGhrayebJChimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembrane TNF-a and activates immune effector functionsCytokine199572512597640345
   PubMed Web of Science ®Google Scholar
• KleynCEGriffithsCEInfliximab for the treatment of psoriasisExpert Opin Biol Ther20066879780516856801
   PubMed Web of Science ®Google Scholar
• Di SabatinoACiccocioppoRCinqueBDefective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s diseaseGut200453707714684579
   PubMed Web of Science ®Google Scholar
• GravesJENunleyKHeffernanMPOff-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)J Am Acad Dermatol2007565579
   PubMedGoogle Scholar
• RuzzettiMSaracenoRCarboniIPapoutsakiMChimentiSType III juvenile pityriasis rubra pilaris: a successful treatment with infliximabJ Eur Acad Dermatol Venereol200822111711818181990
   PubMed Web of Science ®Google Scholar
• MössnerRSchönMPReichKTumor necrosis factor antagonists in the therapy of psoriasisClin Dermatol200826548650218755367
   PubMed Web of Science ®Google Scholar
• ChaudhariURomanoPMulcahyLDEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trialLancet20013571842184711410193
   PubMed Web of Science ®Google Scholar
• GottliebABChaudariUMulcahyLDInfliximab monotherapy provides rapid and substantial benefit for plaque-type psoriasisJ Am Acad Dermatol20034882983512789171
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappKInfliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialLancet20053661367137416226614
   PubMed Web of Science ®Google Scholar
• SmithCHAnsteyAVBarkerJNBritish Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005Br J Dermatol2005153348649716120132
   PubMed Web of Science ®Google Scholar
• SteinKRPearceDJFeldmanSRThe impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis careSemin Cutan Med Surg2005241525715900799
   PubMed Web of Science ®Google Scholar
• BrimhallAKKingLNLicciardoneJCJacobeHMenterASafety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trialsBr J Dermatol2008159227428518547300
   PubMed Web of Science ®Google Scholar
• SchmittJZhangZWozelGMeurerMKirchWEfficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trialsBr J Dermatol2008159351352618627372
   PubMed Web of Science ®Google Scholar
• CheifetzAMayerLMonoclonal antibodies, immunogenicity, and associated infusion reactionsMt Sinai J Med20057225025616021319
   PubMed Web of Science ®Google Scholar
• CheifetzASmedleyMMartinSThe incidence and management of infusion reactions to infliximab: a large center experienceAm J Gastroenterol20039861315132412818276
   PubMed Web of Science ®Google Scholar
• GottliebABEvansRLiSInfliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialJ Am Acad Dermatol200451453454215389187
   PubMed Web of Science ®Google Scholar
• DesaiSBFurstDEProblems encountered during anti-tumour necrosis factor therapyBest Pract Res Clin Rheumatol200620475779016979537
   PubMed Web of Science ®Google Scholar
• PuchnerTCKugathasanSKellyKJBinionDGSuccessful desensitization and therapeutic use of infliximab in adult and pediatric Crohn’s disease patients with prior anaphylactic reactionInflamm Bowel Dis200171343711233658
   PubMed Web of Science ®Google Scholar
• DuburqueCLelongJIacobRSuccessful induction of tolerance to infliximab in patients with Crohn’s disease and prior severe infusion reactionsAliment Pharmacol Ther200624585185816918890
   PubMed Web of Science ®Google Scholar
• LequerréTVittecoqOKlemmerNManagement of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatologyJ Rheumatol20063371307131416758513
   PubMed Web of Science ®Google Scholar
• CandonSMoscaARuemmeleFGouletOChatenoudLCézardJPClinical and biological consequences of immunization to infliximab in pediatric Crohn’s diseaseClin Immunol20061181111916125467
   PubMed Web of Science ®Google Scholar
• LecluseLLPiskinGMekkesJRBosJDde RieMAReview and expert opinion on prevention and treatment of infliximab-related infusion reactionsBr J Dermatol2008159352753618627374
   PubMed Web of Science ®Google Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med2003348760160812584368
   PubMed Web of Science ®Google Scholar
• HanauerSBWagnerCLBalaMIncidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s diseaseClin Gastroenterol Hepatol20042754255315224278
   PubMed Web of Science ®Google Scholar
• KapetanovicMCLarssonLTruedssonLSturfeltGSaxneTGeborekPPredictors of infusion reactions during infliximab treatment in patients with arthritisArthritis Res Ther200684R13116869978
   PubMed Web of Science ®Google Scholar
• VermeireSNomanMVan AsscheGBaertFD’HaensGRutgeertsPEffectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s diseaseGut20075691226123117229796
   PubMed Web of Science ®Google Scholar
• CrandallWVMacknerLMInfusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive modelAliment Pharmacol Ther2003171758412492735
   PubMed Web of Science ®Google Scholar
• FarrellRJAlsahliMJeenYTFalchukKRPeppercornMAMichettiPIntravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trialGastroenterology2003124491792412671888
   PubMed Web of Science ®Google Scholar
• SanyJKaiserMJJorgensenCTrapeGStudy of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritisAnn Rheum Dis200564111647164916227416
   PubMed Web of Science ®Google Scholar
• JacobsteinDAMarkowitzJEKirschnerBSPremedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortiumInflamm Bowel Dis200511544244615867583
   PubMed Web of Science ®Google Scholar
• SaracenoRChimentiSHow to manage infections in the era of biologics?Dermatol Ther200821318018618564248
   PubMed Web of Science ®Google Scholar
• American Thoracic SocietyTargeted tuberculin testing and treatment of latent tuberculosis infectionMMWR Recomm Rep200049RR-6151
   Google Scholar
• RaychaudhuriSShmerlingRErmannJHelfgottSDevelopment of active tuberculosis following initiation of infliximab despite appropriate prophylaxisRheumatology (Oxford)200746588788817363399
   PubMed Web of Science ®Google Scholar
• TakahashiHShigeharaKYamamotoMInterferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administrationRheumatol Int200727121143114817503048
   PubMed Web of Science ®Google Scholar
• CohenRDBowieWREnnsRFlintJFitzgeraldJMPulmonary actinomycosis complicating infliximab therapy for Crohn’s diseaseThorax200762111013101417965080
   PubMed Web of Science ®Google Scholar
• KestemanTYombiJCGigiJDurezPListeria infections associated with infliximab: case reportsClin Rheumatol200726122173217517579802
   PubMed Web of Science ®Google Scholar
• GeraghtyEMRistowBGordonSMAronowitzPOverwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritisClin Infect Dis20074410e82e8417443458
   PubMed Web of Science ®Google Scholar
• TektonidouMGSkopouliFNVisceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?Clin Rheumatol200827454154217963018
   PubMed Web of Science ®Google Scholar
• MuñozPGiannellaMValerioMCryptococcal meningitis in a patient treated with infliximabDiagn Microbiol Infect Dis200757444344617240111
   PubMed Web of Science ®Google Scholar
• LeeJHSlifmanNRGershonSKLife-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanerceptArthritis Rheum200246102565257012384912
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRThe promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?Dermatol Ther20041737638215379772
   PubMedGoogle Scholar
• FortuneDGMainCJO’SullivanTMGriffithsCEQuality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stressBr J Dermatol19971377557609415236
   PubMed Web of Science ®Google Scholar
• FeldmanSRGottliebABBalaMInfliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasisBr J Dermatol200815970471018627375
   PubMed Web of Science ®Google Scholar
• KimballABJacobsonCWeissSVreelandMGWuYThe psychosocial burden of psoriasisAm J Clin Dermatol20056638339216343026
   PubMed Web of Science ®Google Scholar
• RigopoulosDGregoriouSStratigosAEvaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label studyBr J Dermatol2008159245345618565184
   PubMed Web of Science ®Google Scholar
• De JongEMSeegersBAGulinckMKBoezemanJBvan de KerkhofPCPsoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patientsDermatology199619343003038993953
   PubMed Web of Science ®Google Scholar
• CohenMRRedaDJCleggDOBaseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative SpondyloarthropathiesJ Rheumatol19992681752175610451073
   PubMed Web of Science ®Google Scholar
• JonesSMArmasJBCohenMGLovellCREvisonGMcHughNJPsoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin diseaseBr J Rheumatol19943398348398081668
   PubMedGoogle Scholar
• BakerHGoldingDNThompsonThe nails in psoriatic arthritisBr J Dermatol19647654965414242177
   PubMed Web of Science ®Google Scholar
• WrightVRobertsMCHillAGDermatological manifestations in psoriatic arthritis: a follow-up studyActa Derm Venereol197959323524087081
   PubMed Web of Science ®Google Scholar
• GladmanDDShuckettRRussellMLThorneJCSchachterRKPsoriatic arthritis (PSA) – an analysis of 220 patientsQ J Med1987622381271413659255
   PubMedGoogle Scholar
• TanALBenjaminMToumiHThe relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis – a high-resolution MRI and histological studyRheumatology (Oxford)200746225325616837473
   PubMed Web of Science ®Google Scholar
• KaneDStaffordLBresnihanBFitzGeraldOA classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis – ‘DIP or not DIP revisited’Rheumatology (Oxford)200342121469147612867577
   PubMed Web of Science ®Google Scholar
• WilliamsonLDalbethNDockertyJLGeeBCWeatherallRWordsworthBPExtended report: nail disease in psoriatic arthritis – clinically important, potentially treatable and often overlookedRheumatology (Oxford)200443679079415113998
   PubMed Web of Science ®Google Scholar
• ScarpaRMangusoFOrienteAPelusoRAttenoMOrientePIs the involvement of the distal interphalangeal joint in psoriatic patients related to nail psoriasis?Clin Rheumatol2004231273014749978
   PubMed Web of Science ®Google Scholar
• SerarslanGGülerHKarazincirSThe relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasisClin Rheumatol20072681245124717119859
   PubMed Web of Science ®Google Scholar
• BianchiLBergaminAde FeliceCCapriottiEChimentiSRemission and time of resolution of nail psoriasis during infliximab therapyJ Am Acad Dermatol200552473673715793554
   PubMed Web of Science ®Google Scholar
• LawryMBiological therapy and nail psoriasisDermatol Ther2007201606717403261
   PubMed Web of Science ®Google Scholar
• CassellSKavanaughAFTherapies for psoriatic nail disease. A systematic reviewJ Rheumatol20063371452145616724366
   PubMed Web of Science ®Google Scholar
• TaylorWJEpidemiology of psoriatic arthritisCurr Opin Rheumatol20021429810311845012
   PubMed Web of Science ®Google Scholar
• McHughNJBalachrishnanCJonesSMProgression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective studyRheumatology200342677878312730539
   PubMed Web of Science ®Google Scholar
• FelsonDTAndersonJJBoersMAmerican College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisArthritis Rheum19953867277357779114
   PubMed Web of Science ®Google Scholar
• AntoniCEKavanaughAKirkhamBSustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis Rheum20055241227123615818699
   PubMed Web of Science ®Google Scholar
• AntoniCKruegerGGde VlamKIMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialAnn Rheum Dis20056481150115715677701
   PubMed Web of Science ®Google Scholar
• KavanaughAAntoniCEGladmanDThe Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearAnn Rheum Dis20066581038104316439444
   PubMed Web of Science ®Google Scholar
• ReichKGriffithsCBarkerJRecommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensusDermatology2008217326827518685261
   PubMed Web of Science ®Google Scholar